Shanghai Clinic Treats First Global Patient with Solid Tumor CAR-T

Josh, who suffers from advanced gastroduodenal cancer, turned to the Shanghai facility after exhausting traditional treatment options in his home country. Diagnostic testing confirmed his eligibility for the therapy, which specifically targets Claudin 18.2-positive, HER2-negative tumors. Having completed the initial leukapheresis stage, the patient is now awaiting the reinfusion of his manufactured CAR-T cells, a process scheduled for the coming weeks.

Satri-cel recently received regulatory approval in China, positioning the nation as a primary hub for advanced oncology innovation. Dr. Linli Xuan, Chief of Medical Oncology at Jiahui, noted that the facility is seeing rising demand from global patients seeking clinical breakthroughs that have yet to reach Western markets. The center utilizes a specialized international office to manage the logistics of overseas patients, providing a streamlined model for complex cellular treatments that require multidisciplinary oversight.